MDM2 and cancer: Because dysfunction of the p53 pathway by other reasons, such as the overexpression of MDM2/MDM4, is also often found in other human cancers [1], therapies containing carfilzomib might be an effective strategy for other human cancers with reduced p53 dosage or loss.